# Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL

> **NCT03349281** · PHASE1 · COMPLETED · sponsor: **Julio Barredo, MD** · enrollment: 6 (actual)

## Conditions studied

- Refractory Acute Lymphoblastic Leukemia
- Relapsed Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Pevonedistat
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** PEG-asparaginase
- **DRUG:** Doxorubicin
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Hydrocortisone

## Key facts

- **NCT ID:** NCT03349281
- **Lead sponsor:** Julio Barredo, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-25
- **Primary completion:** 2021-08-11
- **Final completion:** 2022-10-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2022-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349281, "Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03349281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*